Cargando…

NI-13 Prediction of outcome at the time of discontinuing TMZ-adjuvant therapy in IDH-mutant lower grade glioma using (11)C-methinine PET

Purpose: This study aimed to clarify whether positron emission tomography with (11)C-methyl-L-methionine ((11)C-met PET) can predict consequential outcomes at the time of discontinuing temozolomide (TMZ)-adjuvant chemotherapy in patients with residual isocitrate dehydrogenase gene (IDH)-mutant lower...

Descripción completa

Detalles Bibliográficos
Autores principales:	Beppu, Takaaki, Sato, Yuichi, Sasaki, Toshiaki, Terasaki, Kazunori, Iwaya, Takeshi, Ogasawara, Kuniaki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Supplement Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8648249/ http://dx.doi.org/10.1093/noajnl/vdab159.075

Ejemplares similares

NI-19 Use of (11)C-methionine PET for decision of discontinuation of adjuvant chemotherapy with temozolomide
por: Beppu, Takaaki, et al.
Publicado: (2020)

PET With (11)C-Methyl-l-Methionine as a Predictor of Consequential Outcomes at the Time of Discontinuing Temozolomide-Adjuvant Chemotherapy in Patients With Residual IDH-Mutant Lower-Grade Glioma
por: Beppu, Takaaki, et al.
Publicado: (2022)

Impacts on Histological Features and (11)C-Methyl-L-methionine Uptake After “One-Shot” Administration with Bevacizumab Before Surgery in Newly Diagnosed Glioblastoma()
por: Beppu, Takaaki, et al.
Publicado: (2019)

NI-11 PATHOLOGICAL ASSESSMENT IN THE IMPACT OF ONE-SHOT BEVACIZUMAB ON UPTAKE OF (11)C-METHIONINE
por: Beppu, Takaaki, et al.
Publicado: (2019)

CBMS-1 Targeting amino acid metabolic vulnerabilities in IDH-mutant and IDH-wildtype gliomas
por: Ohba, Shigeo, et al.
Publicado: (2021)

Predictive value of MGMT promoter methylation on the survival of TMZ treated IDH-mutant glioblastoma
por: Chai, Ruichao, et al.
Publicado: (2021)

NI-6 Preoperative differential diagnosis of grade II and grade III in cases with astrocytoma, IDH mutant
por: Yano, Hirohito, et al.
Publicado: (2021)

Biological Characteristics of a Cerebellar Mass Regrowing after Removal in a Patient with Lhermitte-Duclos Disease: Emission Tomography Studies
por: Saito, Hideo, et al.
Publicado: (2014)

NI-10 CLINICAL BENEFITS FROM ONE-SHOT BEVACIZUMAB BEFORE A RESECTION OF GLIOBLASTOMA
por: Beppu, Takaaki, et al.
Publicado: (2022)

High-uptake areas on positron emission tomography with the hypoxic radiotracer (18)F-FRP170 in glioblastomas include regions retaining proliferative activity under hypoxia
por: Beppu, Takaaki, et al.
Publicado: (2015)

DDRE-12. HETEROGENOUS RESPONSE OF IDH-MUTANT AND IDH-WT GLIOMA TO NAMPT INHIBITION
por: Rahman, Masum, et al.
Publicado: (2021)

Utility of arterial spin labeling for objective assessment of intratumoral microvessels in diffuse hemispheric glioma, H3 G34R-mutant: A case report and literature review
por: Kitakami, Kei, et al.
Publicado: (2022)

BIMG-20. METABOLIC BIOMARKERS IN MICRODIALYSATE OF IDH-1 MUTANT TUMORS
por: Rajani, Karishma, et al.
Publicado: (2021)

The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033
por: Bady, Pierre, et al.
Publicado: (2018)

NGMA-1. Quantification of IDH mutant alleles predicts outcome in diffuse gliomas
por: Voisin, Mathew, et al.
Publicado: (2021)

NI-12 The ratio of T1-Weighted to T2-Weighted Signal Intensity and IDH mutation in glioma
por: Sanada, Takahiro, et al.
Publicado: (2021)

DDRE-29. DE NOVO PYRIMIDINE SYNTHESIS IS A TARGETABLE VULNERABILITY IN IDH-MUTANT GLIOMA
por: Shi, Diana D, et al.
Publicado: (2021)

MPC-2 Clinical course and prognosis of lower-grade glioma, IDH wildtype and pTERT mutant
por: Takahashi, Yoshinobu, et al.
Publicado: (2021)

FSMP-07. CYSTATHIONINE-Γ-LYASE DRIVES ANTIOXIDANT DEFENSE IN CYSTEINE-RESTRICTED IDH1 MUTANT ASTROCYTOMAS
por: Cano-Galiano, Andrés, et al.
Publicado: (2021)

MPC-10 Prognostic analysis in IDH mutant astrocytoma patient with CDKN2A/B homozygous deletion
por: Yanagisawa, Shunsuke, et al.
Publicado: (2021)

ML-09 The REAL-WORLD of Elderly PCNSL Therapy in Tohoku and Niigata Area According to Retrospective Analysis: A Collaborative Investigation of the Tohoku Brain Tumor Study Group
por: Asano, Kenichiro, et al.
Publicado: (2020)

BIMG-22. DEEP LEARNING SUPER-RESOLUTION MR SPECTROSCOPIC IMAGING TO MAP TUMOR METABOLISM IN MUTANT IDH GLIOMA PATIENTS
por: Li, Xianqi, et al.
Publicado: (2021)

DDRE-03. IDH1-MUTANT GBM CELLS ARE HIGHLY SENSITIVE TO COMBINATION OF KDM6A/B AND HDAC INHIBITORS
por: Kayabölen, Alişan, et al.
Publicado: (2021)

Detection of Retinal Hemangioblastomas in von Hippel–Lindau Disease Using Three-Dimensional Arterial Spin Labeling MR Imaging at 3T
por: Nomura, Jun-ichi, et al.
Publicado: (2016)

Apparent diffusion coefficient and arterial spin labeling perfusion of conventional chondrosarcoma in the parafalcine region: a case report
por: Kojima, Daigo, et al.
Publicado: (2017)

Detection of misery perfusion in the cerebral hemisphere with chronic unilateral major cerebral artery steno-occlusive disease using crossed cerebellar hypoperfusion: comparison of brain SPECT and PET imaging
por: Matsumoto, Yoshiyasu, et al.
Publicado: (2013)

BIMG-15. LACTATE AND GLUTATHIONE LEVELS DETECTED WITH PROTON MR SPECTROSCOPY ARE ASSOCIATED WITH POOR SURVIVAL IN IDH WILD TYPE TERTP MUTANT DIFFUSE GLIOMAS
por: Sacli-Bilmez, Banu, et al.
Publicado: (2021)

MPC-02 Prognostic effects of molecular factors in elderly patients with IDH-wildtype Glioblastomas
por: Fukai, Junya, et al.
Publicado: (2020)

Primary Cranial Vault Lymphoma Extending between Subcutaneous Tissue and Brain Parenchyma without Skull Destruction after Mild Head Trauma: A Case Report and Literature Review
por: Setta, Kengo, et al.
Publicado: (2021)

BIMG-05. TO BE OR NOT TO BE GLYCOLYTIC: DEUTERATED GLUCOSE-BASED ASSESSMENT OF THE WARBURG EFFECT ALLOWS NON-INVASIVE IMAGING OF TUMOR BURDEN AND TREATMENT RESPONSE IN MUTANT IDH GLIOMAS IN VIVO
por: Taglang, Celine, et al.
Publicado: (2021)

CLRM-03. BGB-290 AND TEMOZOLOMIDE IN TREATING ISOCITRATE DEHYDROGENASE (IDH)1/2-MUTANT GRADE I-IV GLIOMAS – A NOVEL MODEL OF AYA TRIAL DEVELOPMENT AND DEPLOYMENT
por: Marks, Asher, et al.
Publicado: (2021)

OKN-007 Increases temozolomide (TMZ) Sensitivity and Suppresses TMZ-Resistant Glioblastoma (GBM) Tumor Growth()()
por: Towner, Rheal A., et al.
Publicado: (2018)

NI-1 METHYLTHIOADENOSINE PHOSPHOLYLASE STATUS CORRELATES WITH PROGNOSIS AND METHIONINE UPTAKE IN IDH MUTANT ASTROCYTOMA
por: Yamamura, Toshihiro, et al.
Publicado: (2022)

Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome
por: DiNardo, Courtney D., et al.
Publicado: (2022)

Synergy between TMZ and individualized multimodal immunotherapy to improve overall survival of IDH1 wild-type MGMT promoter-unmethylated GBM patients
por: Van Gool, Stefaan W., et al.
Publicado: (2022)

Fractional anisotropy in the centrum semiovale as a quantitative indicator of cerebral white matter damage in the subacute phase in patients with carbon monoxide poisoning: correlation with the concentration of myelin basic protein in cerebrospinal fluid
por: Beppu, Takaaki, et al.
Publicado: (2012)

Therapies for IDH-Mutant Gliomas
por: Alshiekh Nasany, Ruham, et al.
Publicado: (2023)

MPC-8 Serum anti-zinc finger FYVE domain-containing protein 21 (ZFYVE21) autoantibody as a novel biomarker for oligodendroglioma IDH-mutant and 1p/19q co-deletion
por: Matsutani, Tomoo, et al.
Publicado: (2021)

Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers
por: Unruh, Dusten, et al.
Publicado: (2019)

Postoperative risk of IDH-mutant glioma–associated seizures and their potential management with IDH-mutant inhibitors
por: Drumm, Michael R., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_eem8i06v31ca0ijb3qnfl3rg6k